Duration of Acute and Chronic Toxicity Testing in Animals (ICH S4A and S4B): Duration of Acute and Chronic Toxicity Testing in Animals (ICH S4A and S4B)
Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Formidling
Standard
Duration of Acute and Chronic Toxicity Testing in Animals (ICH S4A and S4B) : Duration of Acute and Chronic Toxicity Testing in Animals (ICH S4A and S4B). / Spindler, Per; Van Cauteren, Herman.
Global Approach in Safety Testing: ICH Guidelines Explained: Global Approach in Safety Testing: ICH Guidelines Explained. Bind 1 1. udg. Springer Publishing Company, 2013. s. 159-174 (AAPS Advances in the Pharmaceutical Sciences Series (Book 5)).Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Formidling
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - CHAP
T1 - Duration of Acute and Chronic Toxicity Testing in Animals (ICH S4A and S4B)
T2 - Duration of Acute and Chronic Toxicity Testing in Animals (ICH S4A and S4B)
AU - Spindler, Per
AU - Van Cauteren, Herman
PY - 2013/2/1
Y1 - 2013/2/1
N2 - To support approval of pharmaceuticals for long term use in humans it is required that product safety is supported by acute and chronic toxicity studies in rodents and non-rodents. The duration of acute toxicity studies (S4A) and chronic rodent studies (S4B) were harmonised between the three ICH regions in 1991; whereas the process of harmonising the duration of non-rodent studies was initiated. The US FDA originally required studies of at least 12 months duration, whereas in Japan and EU studies of 6 months duration were considered acceptable as an ICH objective. In this chapter, the background for the ICH S4B guideline regarding the duration of non-rodent repeated dose toxicity studies is explained and lessons learned are discussed. Since the guideline was issued in 1997 changes occurred in e.g. the language of the European legislation, and the requirements for non-clinical studies to support clinical development has progressed within the ICH (M3): we therefore consider options such as prospective evaluation, biomarker-based mechanistic understanding, toxicokinetics and the use of evidence-based medicine to support further joint activities to harmonise the duration of non-rodent toxicity studies at the global level.
AB - To support approval of pharmaceuticals for long term use in humans it is required that product safety is supported by acute and chronic toxicity studies in rodents and non-rodents. The duration of acute toxicity studies (S4A) and chronic rodent studies (S4B) were harmonised between the three ICH regions in 1991; whereas the process of harmonising the duration of non-rodent studies was initiated. The US FDA originally required studies of at least 12 months duration, whereas in Japan and EU studies of 6 months duration were considered acceptable as an ICH objective. In this chapter, the background for the ICH S4B guideline regarding the duration of non-rodent repeated dose toxicity studies is explained and lessons learned are discussed. Since the guideline was issued in 1997 changes occurred in e.g. the language of the European legislation, and the requirements for non-clinical studies to support clinical development has progressed within the ICH (M3): we therefore consider options such as prospective evaluation, biomarker-based mechanistic understanding, toxicokinetics and the use of evidence-based medicine to support further joint activities to harmonise the duration of non-rodent toxicity studies at the global level.
KW - Faculty of Health and Medical Sciences
KW - International Conference on Harmonisation of Technical Requirements for Pharmaceuticals
KW - ICH
KW - pharmaceuticals
KW - Drug Discovery
KW - medicine
KW - regulatory science
M3 - Book chapter
SN - 1461459494
VL - 1
T3 - AAPS Advances in the Pharmaceutical Sciences Series (Book 5)
SP - 159
EP - 174
BT - Global Approach in Safety Testing: ICH Guidelines Explained
PB - Springer Publishing Company
ER -
ID: 90204573